Breast Cancer Edition: Top Headlines for Week of October 3, 2022

In this episode, FDA approves Rolvedon to reduce infection incidence; women want more education on sexual health during treatment; abemaciclib regimen shows further signs of benefit and more.

Read the full coverage here:

FDA approves Rolvedon to reduce infection incidence when taking certain anticancer drugs

Women with breast cancer want more education on sexual health during treatment

Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup

Cancer-related fatigue may impact balance after breast cancer treatment

Chronic inflammation linked to cognitive difficulties among older breast cancer survivors

References:

Carroll JE, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.00406.

Goetz MP, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris.

Huynh V, et al. Ann Surg Oncol. 2022;doi:10.1245/s10434-022-12126-7.

Press Release

Wechsler S, et al. Rehab Oncol. 2022;doi:10.1097/01.REO.0000000000000308.